Core Viewpoint - The company is preparing for its 2024 Annual General Meeting (AGM) scheduled for June 23, 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [2][3][4]. Meeting Agenda - The AGM will cover various proposals including the 2024 Board of Directors' work report, financial reports, profit distribution plans, and the election of directors and supervisors [3][4][14]. - A proposal regarding loans from China Construction Bank and Bank of China, guaranteed by the company, will also be discussed [3][14]. Financial Performance - The company reported a net profit of 722 million yuan for 2024, a decrease of 25.36% year-on-year, indicating challenges in the dairy industry due to fluctuations in raw milk prices and changing market demands [9][10]. - The company aims to adapt to new market conditions and maintain high-quality product offerings despite short-term challenges [9][10]. Governance and Compliance - The company has revised its governance structures and compliance protocols in line with relevant laws and regulations to enhance operational efficiency and protect shareholder rights [9][10][12]. - The company has established a risk management framework to mitigate financial risks associated with its operations [12][13]. Strategic Initiatives - The company is focusing on digital transformation to improve operational efficiency and enhance sales through e-commerce channels [11][12]. - It is also exploring low-carbon practices and sustainable development initiatives to align with industry trends and consumer preferences [13][20]. Shareholder Engagement - The company is committed to maintaining transparent communication with shareholders, utilizing various platforms for investor relations and feedback [18][19]. - The company has implemented a reminder service for shareholders to ensure participation in the AGM and voting processes [5][6]. Independent Directors' Reports - Independent directors have actively participated in governance, ensuring compliance and protecting the interests of minority shareholders [21][24][31]. - They have focused on key issues such as financial audits, executive compensation, and related party transactions [23][27][32].

8200万！广 东"珠海年鱼+荔 枝"CP香港行斩 获大单_南方+_ 南方plus 6月12日下午， 广东（珠海）特 色农产品进香港 活动在香港大埔 举行。珠海年鱼 携手广东荔枝跨 越港珠澳大桥， 以"鲜香+甜 蜜"的组合拳叩 响香港市场大 门。 广东（珠海）特色农产品进香港活动现场。 现在，珠海的中 早熟荔枝佳品妃 子笑、桂味进入 最佳赏味期；而 在粤西地区，糯 米糍、仙进奉等 中晚熟高品质荔 枝开始大量上 市。广东各个荔 枝产区、各个荔 枝品种都正 以"争奇斗艳"的 姿态向市场涌 入，广东省农业 农村厅更是联合 各个荔枝产区发 起了"喊全球吃 广东荔枝"系列 推介活动。 此次活动由广东 省农业农村厅指 导，珠海市农业 农村局和香港有 机认证中心共同 主办。广东省农 业农村厅厅长刘 棕会、香港渔农 自然护理署渔业 主任陈璚、珠海 市人大常委会专 职委员刘江成、 珠海市农业农村 局局长黄顺安、 香港有机认证中 心主席、大埔社 团联谊会主席文 春辉、香港农业 联合会主席陈建 业、香港物流商 会主席钟鸿兴等 参加活动。 与会嘉宾为广东荔枝打call，并喊全球吃广东荔枝。 港珠再度牵手 年鱼荔枝CP斩 获大单 活动 ...

Core Insights - Shanghai Pharmaceuticals reported a solid performance in Q1 2025, achieving a revenue of 70.763 billion yuan, a year-on-year increase of 0.87%, with a net profit attributable to shareholders of 1.333 billion yuan and R&D investment of 0.612 billion yuan [1] Pharmaceutical Industry Segment - The company made progress in R&D with multiple product approvals and advancements in innovative drug development and traditional Chinese medicine projects [2] - Key clinical trials for several innovative drugs are ongoing, including I001 for hypertension and B001 for neuromyelitis optica spectrum disorder, with significant patient enrollment completed [2] - The establishment of several research centers in Shanghai enhances the collaborative R&D framework [2] - New products launched include ursodeoxycholic acid capsules and omeprazole sodium bicarbonate suspension, with additional products submitted for production approval [2] - The company has achieved consistency evaluation for 77 products, totaling 106 specifications [2] Traditional Chinese Medicine Business - The company is advancing the secondary development of major traditional Chinese medicine products, with significant progress in evidence-based research [3] - Collaboration with Tianjin University of Traditional Chinese Medicine has led to published research and recognition for quality improvement in traditional Chinese medicine [3] - A comprehensive strategy for securing quality medicinal materials from the source is being implemented, focusing on digital transformation and standardized management [3] Pharmaceutical Commercial Segment - The company achieved a sales revenue of 8.6 billion yuan from its import agency business, reflecting a year-on-year growth of 9.0% [4] - The establishment of a drug and medical device import-export service center in the Lingang New Area supports the import of urgently needed drugs and rare disease medications [4] - Strategic partnerships with companies like AstraZeneca and CanSino Biologics have been formed to enhance the commercialization of new drugs, with innovative drug business revenue reaching 12.5 billion yuan, a growth of 23.2% [4] - The medical device health business generated 10.9 billion yuan in sales, marking a 6.9% increase [4] - The company aims to leverage its full industry chain resources and collaborate with academic and research institutions to foster innovation and enhance competitiveness [4]

成立于2011年的一亩田作为一家覆盖农业全产业链的产业互联网企业，致力于以数字技术推动农业 产业转型发展。 覆盖种植、批发、流通等农业全产业链的综合性数字集团企业。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，中国证监会国际合作司于2025年2月17日披露了《关于YIMUTIAN INC.（一亩 田集团）境外发行上市备案通知书》。 根据备案通知书，一亩田计划发行不超过196,169,769股普通股并在美国纳斯达克证券交易所上 市。 以搭建农产品B2B数字化产销服务平台开始，一亩田逐步发展成为覆盖种植、批发、流通等农业全 产业链的综合性数字集团企业，旗下 现拥有 一亩田APP数字平台、豆牛智慧代卖、沃众田数字规模 化种植基地、区域产业服务等业务板块，形成农业全产业链数字化服务创新模式。 其中， 围绕"卖货"难题，一亩田搭建 了 全国最大的农产品B2B流通数字服务平台——一亩田APP ， 为B端农产品买卖双方提供信息撮合、精准营销、在线交易、行情查询等综合服务 。目前，平台 采供B端用户超过5600万，全年可售卖农产品品类超过1.5万，包括瓜果蔬菜、 ...